

Product datasheet for TL311603V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

MAGED1 Human shRNA Lentiviral Particle (Locus ID 9500)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: MAGED1 Human shRNA Lentiviral Particle (Locus ID 9500)

Locus ID: 9500

Synonyms: DLXIN-1; NRAGE

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: MAGED1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001005332, NM 001005333, NM 006986, NM 001005333.1, NM 001005332.1,

NM 006986.1, NM 006986.2, NM 006986.3, BC014070, BC014070.2, BC032473, BC032473.2,

NM 001005333.2, NM 006986.4, NM 001005332.2

UniProt ID: Q9Y5V3

Summary: This gene is a member of the melanoma antigen gene (MAGE) family. Most of the genes of

this family encode tumor specific antigens that are not expressed in normal adult tissues except testis. Although the protein encoded by this gene shares strong homology with members of the MAGE family, it is expressed in almost all normal adult tissues. This gene has been demonstrated to be involved in the p75 neurotrophin receptor mediated programmed cell death pathway. Three transcript variants encoding two different isoforms have been

found for this gene. [provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).